0OIR Stock Chart & Stats
kr227.63
kr0.40(0.18%)
At close: 4:00 PM EDT
kr227.63
kr0.40(0.18%)
Day’s Range― - ―
52-Week Rangekr195.40 - kr271.60
Previous CloseN/A
Volume10.43K
Average Volume (3M)17.75K
Market Cap
kr46.79B
Enterprise Valuekr52.87K
Total Cash (Recent Filing)kr316.00M
Total Debt (Recent Filing)kr990.00M
Price to Earnings (P/E)34.8
Beta0.51
Next Earnings
Nov 17, 2026EPS Estimate
1.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.28
Shares Outstanding202,567,200
10 Day Avg. Volume24,606
30 Day Avg. Volume17,753
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ALK-abello News
0OIR FAQ
What was ALK-abello A/S Class B’s price range in the past 12 months?
ALK-abello A/S Class B lowest share price was kr195.40 and its highest was kr271.60 in the past 12 months.
What is ALK-abello A/S Class B’s market cap?
ALK-abello A/S Class B’s market cap is kr46.79B.
When is ALK-abello A/S Class B’s upcoming earnings report date?
ALK-abello A/S Class B’s upcoming earnings report date is Nov 17, 2026 which is in 81 days.
How were ALK-abello A/S Class B’s earnings last quarter?
ALK-abello A/S Class B released its earnings results on Aug 20, 2026. The company reported kr1.5 earnings per share for the quarter, the consensus estimate of kr1.5 by kr0.
Is ALK-abello A/S Class B overvalued?
According to Wall Street analysts ALK-abello A/S Class B’s price is currently Overvalued.
Does ALK-abello A/S Class B pay dividends?
ALK-abello A/S Class B does not currently pay dividends.
What is ALK-abello A/S Class B’s EPS estimate?
ALK-abello A/S Class B’s EPS estimate is 1.7.
How many shares outstanding does ALK-abello A/S Class B have?
ALK-abello A/S Class B has 202,567,200 shares outstanding.
What happened to ALK-abello A/S Class B’s price movement after its last earnings report?
ALK-abello A/S Class B reported an EPS of kr1.5 in its last earnings report, expectations of kr1.5. Following the earnings report the stock price went down -4.182%.
Which hedge fund is a major shareholder of ALK-abello A/S Class B?
Currently, no hedge funds are holding shares in GB:0OIR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ALK-abello A/S Class B
ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
0OIR Company Deck
0OIR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong top-line and cash-generation performance driven by tablet momentum, robust pipeline progress (peanut Phase III planning, China ACARIZAX readout) and an upgraded revenue range, while also acknowledging near-term cost increases and regulatory/market-access headwinds—most notably the German rebate increase and U.K. rollout delays for neffy. Management outlined mitigation plans and maintained long-term ambitions, suggesting confidence in growth despite some regional and timing uncertainties.View all GB:0OIR earnings summariesTechnical Analysis
ALK-abello
―
―
Inovio Pharmaceuticals
―
Aclaris Therapeutics
―
Emergent Biosolutions
―
Novartis
―
Bristol-Myers Squibb
―